India Coldrif Cough Syrup Ban
Analysis based on 7 articles · First reported Oct 07, 2025 · Last updated Oct 07, 2025
The event has a significant negative impact on the pharmaceutical market, particularly for generic drug manufacturers in India, as it raises concerns about quality control and regulatory oversight. The reputation of India as a major supplier of generic medicines globally is at risk, potentially affecting export markets and investor confidence in the sector.
The India — Punjab, India government has banned the sale, distribution, and use of Coldrif cough syrup after 14 children died in India — Madhya Pradesh due to consumption of the contaminated medicine. The syrup, manufactured by Sresan Pharmaceuticals in India — Tamil Nadu, was found to contain dangerously high levels of Diethylene Glycol (DEG), a toxic substance. This tragic event has triggered a national health alert, leading to similar bans and advisories in other states including India — Uttar Pradesh, India — Rajasthan, India — Kerala, India — Tamil Nadu, India — Uttarakhand, India — Telangana, India — Goa, India — Himachal Pradesh, India — Karnataka, and India — Maharashtra. Authorities have initiated criminal cases against the manufacturer and prescribing doctor, and the India — Central Drugs Standard Control Organisation has launched risk-based inspections of various drugs. The incident highlights critical issues in drug safety and quality control within India's pharmaceutical industry, impacting its global standing as a generic medicine supplier.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard